



PRIVI SPECIALITY CHEMICALS LTD

01 AUGUST 2025

WHY IT IS A BUY:

- With a growth in Net Profit of 43.87% the company declared outstanding results in March 2025.
- Piotroski Score is at 8.00 a very strong score indicating a company with solid financial strength and fundamental performance.
- ROCE Highest at 15.2% and Debit to Equity Ratio lowest at 1.04 times.
- With ROCE of 14.5, it has a very expensive valuation with a 5.1 enterprise value to Capital Employed.
- Stock is technically in a BULLISH stance: Monthly chart Flag with Pole breakout.
- Rise in Institutional Holdings at 5.37%.

Product Portfolio: High value aroma chemicals including Dihydromyrcenol, Camphor, Amber Fleur, Terpineol, Galaxmusk, Indomerane, Florovane. Over 10 products have >20% global market share.

R&D Innovation: 2 state of the art R&D centres in Maharashtra. New product development bio refinery using agri - bio waste, green chemistry.

Manufacturing & Integration: 8 manufacturing units CST Processing Capacity 36000 MTPA. GTO Processing Capacity 9600 MTPA.

Investors Returns (3 years)


Period	6M	1Y	2Y	3Y
Stock (%)	46.99%	62.08%	135.54%	107.90%
Sector (%)	18.38%	18.38%	60.03%	54.83%
Sensex (%)	5.24%	-0.22%	22.59%	41.67%

PRIVI SPECIALITY CHEMICALS LTD


01 AUGUST 2025

Company has declared positive results


The company's ability to manage interest payments is improving.



Near term Operating Profit trend is quite positive



Near term PBT trend is very positive





PRIVI SPECIALITY CHEMICALS LTD

01 AUGUST 2025

QUARTERLY RESULTS:

Consolidated Figures in Rs. Crores

	Sep-23	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24	Mar-25
Sales	455	404	484	464	533	491	614
Expenses	366	314	393	370	423	378	481
Operating Profit	89	90	91	94	110	113	133
OPM%	20%	22%	19%	20%	21%	23%	22%
Other Income	7	6	8	3	4	2	15
Interest	25	24	25	22	22	22	23
Depreciation	31	32	30	32	32	32	35
Profit before tax	40	39	44	43	61	61	90
Ta%	25%	26%	28%	27%	26%	27%	29%
Net Profit	30	29	32	31	45	44	64
EPS in Rs	7.80	7.36	7.93	8.02	11.42	11.37	17.01

ANNUAL RESULTS:

Consolidated Figures in Rs. Crores

	Mar-19	Mar-20	Mar-21	Mar-22	Mar-23	Mar-24	Mar-25
Sales	1341	1324	1277	1404	1608	1752	2101
Expenses	1128	1104	1067	1209	1420	1423	1643
Operating Profit	213	221	210	195	188	329	458
OPM %	16%	17%	16%	14%	12%	19%	22%
Other Income	14	66	43	38	21	26	20
Interest	29	38	24	25	70	102	92
Depreciation	47	57	71	75	108	123	132
Profit before tax	152	193	158	133	31	130	255
Tax %	38%	24%	26%	27%	31%	27%	27%
Net Profit	94	146	117	97	21	95	185
EPS in Rs	24.10	37.35	29.90	24.91	5.68	24.27	47.83

PRIVI SPECIALITY CHEMICALS LTD

01 AUGUST 2025

BALANCE SHEET:

Consolidated Figures in Rs. Crores

	Mar-19	Mar-20	Mar-21	Mar-22	Mar-23	Mar-24	Mar-25
Equity Capital	39	39	39	39	39	39	39
Reserves	537	573	683	773	790	885	1064
Borrowings	491	510	538	933	1079	1008	1143
Other Liabilities	359	262	280	431	483	410	544
Total Liabilities	1426	1384	1540	2176	2391	2343	2791
Fixed Assets	498	598	598	704	1017	1034	1556
CWIP	95	30	175	373	100	99	141
Investments	0	1	0	12	7	40	8
Other Assets	1426	1384	1540	2176	2391	2343	2791
Total Assets	752	793	972	1088	1251	1478	1731

SHAREHOLDING PATTERN:

Numbers in percentages

	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24	Mar-25	Jun-25
PROMOTERS	74.05%	74.05%	74.05%	74.05%	74.05%	74.05%	69.89%
FII	0.96%	0.62%	0.48%	0.43%	0.48%	0.40%	1.47%
DII	3.39%	3.37%	2.84%	2.49%	2.09%	1.95%	3.90%
PUBLIC	21.59%	21.95%	22.62%	23.02%	23.38%	23.62%	24.73%



B.N.RATHI
SECURITIES LIMITED

PRIVI SPECIALITY CHEMICALS LTD

01 AUGUST 2025

TECHNICAL ANALYSIS:



The above monthly chart of prices are traded higher since the March 2020 to Jan 2022. Later on the prices took correction with the lower tops and lower bottoms and breached the pattern of **"Flag with Pole"**. Prices breached the trend line resistance and closed well above the same suggesting the bullishness. The RSI 14 period is trading at 71 levels and breached the trend line resistance which has the potential for the positive stance and we expect the prices to trade higher in the coming months.

Sources:

www.nseindia.com www.bseindia.com www.moneycontrol.com
www.screener.in www.in.tradingview.com



RESEARCH ANALYST: SATISH KUMAR AVUSULA



PRIVI SPECIALITY CHEMICALS LTD

01 AUGUST 2025

Disclaimer:

DISCLOSURES

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

B N Rathi Securities Limited (BNRSL) is a SEBI Registered Research Analyst having registration no. INH000014687. BNRSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services and Depository participant services & BNRSL is a listed public company and the details of the company are available on www.bnrsecurities.com. BNRSL is registered with the Securities & Exchange Board of India (SEBI) for its stock broking & Depository participant business activities.

BNRSL has no material adverse disciplinary history as on the date of publication of this report

I/We, authors (Research team) and the name/s subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my/our views about the subject issuer(s) or securities. I/We also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. I/we or my/our relative or BNRSL does not have any financial interest in the subject company. Also I/we or my/our relative or BNRSL or its Associates may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Since associates of BNRSL are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. I/we or my/our relative or BNRSL or its associates do not have any material conflict of interest. I/we have not served as director, officer or employee in the subject company.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

RESEARCH TEAM

Mr. Satish Kumar Avusula – Fundamental & Technical Analyst

BNRSL or its associates has not received any compensation from the subject company in the past twelve months. BNRSL or its Research Analysts has not been engaged in market making activity for the subject company.

- In the last 12-month period ending on the last day of the month immediately preceding the date of publication of this research report, BNRSL or any of its associates may have:

- i. Received compensation for stock broking services or for any other services from the subject company of this research report and / or;
- ii. Managed or co-managed public offering of the securities from the subject company of this research report and / or;
- iii. Received compensation for products or services other than from the subject company of this research report;

- BNRSL or any of its associates have not received compensation or other benefits from the subject company of this research report or any other third-party in connection with this report

TERMS & CONDITIONS

This report has been prepared by BNRSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of BNRSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. BNRSL will not treat recipients as customers by virtue of their receiving this report.



PRIVI SPECIALITY CHEMICALS LTD

01 AUGUST 2025

DISCLAIMERS

- Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to the recipient's specific circumstances. The securities and strategies discussed and opinions expressed, if any, in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

- This report may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this report should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. Certain transactions, including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. BNRSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. Past performance is not necessarily a guide to future performance. Investors are advised necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

- BNRSL and its affiliated companies, their directors and employees may; (a) from time to time, have long or short position(s) in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities or earn brokerage. The recipient should take this into account before interpreting this document.

- BNRSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that BNRSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific brokerage service transactions. BNRSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

- Neither this report nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. If this report is inadvertently sent or has reached any individual

in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject BNRSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category on investors.

- The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The Company reserves the right to make modifications and alternations to this document as may be required from time to time without any prior notice. The views expressed are those of the analyst(s) and the Company may or may not subscribe to all the views expressed therein.

- Copyright in this document vests with B N Rathie Securities Limited Regd Off: 6-3-652, IV Floor, Kautilya Amrutha Estates, Somajiguda, Hyderabad-500082. Compliance Officer: G Sabith Reddy Email: compliance@bnrsecurities.com, Tel No: 9703703399

Research Entity: **B N Rathie Securities Limited**
SEBI Registration Number: **INH000014687**
CIN: L65993TG1985PLC005838



PRIVI SPECIALITY CHEMICALS LTD

01 AUGUST 2025

MOST IMPORTANT TERMS AND CONDITIONS (MITC)

[Forming part of the Terms and Conditions for providing research services]

1. These terms and conditions, and consent thereon are for the research services provided by the Research Analyst (RA) and RA cannot execute/carry out any trade (purchase/sell transaction) on behalf of, the client. Thus, the clients are advised not to permit RA to execute any trade on their behalf.
2. The fee charged by RA to the client will be subject to the maximum of amount prescribed by SEBI/ Research Analyst Administration and Supervisory Body (RAASB) from time to time (applicable only for Individual and HUF Clients).
Note:
 - 2.1. The current fee limit is Rs 1,51,000/- per annum per family of client for all research services of the RA.
 - 2.2. The fee limit does not include statutory charges.
 - 2.3. The fee limits do not apply to a non-individual client / accredited investor.
3. RA may charge fees in advance if agreed by the client. Such advance shall not exceed the period stipulated by SEBI; presently it is one quarter. In case of pre-mature termination of the RA services by either the client or the RA, the client shall be entitled to seek refund of proportionate fees only for unexpired period.
4. Fees to RA may be paid by the client through any of the specified modes like cheque, online bank transfer, UPI, etc. Cash payment is not allowed. Optionally the client can make payments through Centralized Fee Collection Mechanism (CeFCoM) managed by BSE Limited (i.e. currently recognized RAASB).
5. The RA is required to abide by the applicable regulations/ circulars/ directions specified by SEBI and RAASB from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. The RA will endeavor to promptly inform the client of any conflict of interest that may affect the services being rendered to the client.
6. Any assured/guaranteed/fixed returns schemes or any other schemes of similar nature are prohibited by law. No scheme of this nature shall be offered to the client by the RA.
7. The RA cannot guarantee returns, profits, accuracy, or risk-free investments from the use of the RA's research services. All opinions, projections, estimates of the RA are based on the analysis of available data under certain assumptions as of the date of preparation/publication of research report.
8. Any investment made based on recommendations in research reports are subject to market risks, and recommendations do not provide any assurance of returns. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report. Any reliance placed on the research report provided by the RA shall be as per the client's own judgement and assessment of the conclusions contained in the research report.
9. The SEBI registration, Enlistment with RAASB, and NISM certification do not guarantee the performance of the RA or assure any returns to the client.
10. For any grievances,
 - Step 1: the client should first contact the RA using the details on its website or following contact details:
(RA to provide details as per 'Grievance Redressal / Escalation Matrix')
 - Step 2: If the resolution is unsatisfactory, the client can also lodge grievances through SEBI's SCORES platform at www.scores.sebi.gov.in
 - Step 3: The client may also consider the Online Dispute Resolution (ODR) through the Smart ODR portal at <https://smartodr.in>
11. Clients are required to keep contact details, including email id and mobile number/s updated with the RA at all times.
12. The RA shall never ask for the client's login credentials and OTPs for the client's Trading Account, Demat Account and Bank Account. Never share such information with anyone including RA.

RESEARCH ANALYST: SATISH KUMAR AVUSULA

